Table 1 Demographic and clinical characteristics of the 43 eligible patients
Characteristics | No. of patients |
|---|---|
Eligible patients | 43 |
Gender | |
Female | 43 |
Age (years) | |
Median | 53 |
Range | 32-71 |
ER status | |
Positive | 28(65.1%) |
Negative | 15(34.9%) |
PgR status | |
Positive | 17(39.5%) |
Negative | 26(60.5%) |
HER2 status | |
Positive | 5(11.6%) |
Negative | 38(88.4%) |
BSA | |
<1.25 m2 | 0(0%) |
1.25 m2 ≤ <1.50 m2 | 19(44.2%) |
1.5 m2≤ | 24(55.8%) |
Menopausal states | |
Premenopausal | 22(51.2%) |
Postmenopausal | 21(48.8) |
Histological classification | |
Invasive ductal carcinoma | 41(95.4%) |
Invasive lobular carcinoma | 1(2.3%) |
Apocrine carcinoma | 1(2.3%) |
Stage | |
IIA | 1(2.3%) |
IIB | 17(39.5%) |
IIIA | 4(9.3%) |
IIIB | 6(14.0%) |
IIIC | 15(34.9%) |
Surgery | |
Mastectomy | 24(55.8%) |
Partial resection | 19(44.2%) |
Concurrent radiotherapy | |
Yes | 32(74.4%) |
No | 11(25.6%) |
Concurrent drug | |
Yes | 28(65.1%) |
Tamoxifen | 16(37.2%) |
Letrozol | 10(23.3%) |
Trastuzumab | 1(2.3%) |
Tamoxifen + Trastuzumab | 1(2.3%) |
No | 15(34.9%) |
PSC regimen | |
Anthracycline-based regimen followed by taxane regimen | 36(83.7%) |
Anthracycline-based regimen | 4(9.3%) |
Taxane regimen followed by anthracycline-based regimen | 3(7.0%) |
Clinical response for RPC | |
CR | 3(7.0%) |
PR | 26(60.4%) |
SD | 11(25.6%) |
PD | 3(7.0%) |
Pathological response for RSC | |
Non-p CR | 38(88.4%) |
p CR | 5(11.6%) |